{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:03:11Z","timestamp":1785808991313,"version":"3.56.0"},"reference-count":62,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Rowan University"},{"name":"Cooper Medical School of Rowan University, Biomedical Sciences departmental award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management options for patients. Two new antibiotics, eravacycline and omadacycline, were introduced to the market and have shown promising results in the treatment of Gram-negative infections. Since these drugs are newly available, there is limited in vitro data about their effectiveness against MDR A. baumannii or even susceptible strains. Here, we examined the effectiveness of 22 standard-of-care antibiotics, eravacycline, and omadacycline against susceptible and extensively drug-resistant (XDR) A. baumannii patient isolates from Cooper University Hospital. Furthermore, we examined selected combinations of eravacycline or omadacycline with other antibiotics against an XDR strain. We demonstrated that this collection of strains is largely resistant to monotherapies of carbapenems, fluoroquinolones, folate pathway antagonists, cephalosporins, and most tetracyclines. While clinical breakpoint data are not available for eravacycline or omadacycline, based on minimum inhibitory concentrations, eravacycline was highly effective against these strains. The aminoglycoside amikacin alone and in combination with eravacycline or omadacycline yielded the most promising results. Our comprehensive characterization offers direction in the treatment of this deadly infection in hospitalized patients.<\/jats:p>","DOI":"10.3390\/antibiotics11101298","type":"journal-article","created":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T21:14:28Z","timestamp":1664140468000},"page":"1298","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates"],"prefix":"10.3390","volume":"11","author":[{"given":"Manas S.","family":"Deolankar","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fliorent","sequence":"additional","affiliation":[{"name":"Rowan School of Osteopathic Medicine, Stratford, NJ 08084, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Roh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-2294","authenticated-orcid":false,"given":"Henry","family":"Fraimow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Cooper University Hospital, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-0556","authenticated-orcid":false,"given":"Valerie J.","family":"Carabetta","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"ref_1","first-page":"185","article-title":"Outbreak of multidrug-resistant Acinetobacter baumannii in an intensive care unit","volume":"37","author":"Dettori","year":"2014","journal-title":"New Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1164\/rccm.201102-0349OC","article-title":"High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia","volume":"184","author":"Chung","year":"2011","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/viru.19700","article-title":"Acinetobacter baumannii: An emerging opportunistic pathogen","volume":"3","author":"Howard","year":"2012","journal-title":"Virulence"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jcrc.2010.12.016","article-title":"A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: Antimicrobial and organizational strategies","volume":"26","author":"Consales","year":"2011","journal-title":"J. Crit. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect. Con. Hosp. Epid."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhin.2009.08.015","article-title":"Building a benchmark through active surveillance of intensive care unit-acquired infections: The Italian network SPIN-UTI","volume":"74","author":"Agodi","year":"2010","journal-title":"J. Hosp. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajic.2011.03.010","article-title":"High endemic levels of multidrug-resistant Acinetobacter baumannii among hospitals in southern Brazil","volume":"40","author":"Martins","year":"2012","journal-title":"Am. J. Infect. Cont."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/480463","article-title":"Gram-negative infections in adult intensive care units of Latin America and the Caribbean","volume":"2014","author":"Luna","year":"2014","journal-title":"Crit. Care Res. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12668-019-00658-4","article-title":"World Health Organization report: Current crisis of antibiotic resistance","volume":"9","author":"Rizvanov","year":"2019","journal-title":"BioNanoScience"},{"key":"ref_11","unstructured":"(2022, April 16). Biggest Threats and Data. Antibiotic. Antimicrobial Resistance. CDC, Available online: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html#acine."},{"key":"ref_12","first-page":"430","article-title":"The United States Food and Drug Administration and the end of antibiotics","volume":"34","author":"Shlaes","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jhm.2477","article-title":"Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study","volume":"11","author":"Zilberberg","year":"2016","journal-title":"J. Hosp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/0974-777X.68538","article-title":"Multidrug resistant Acinetobacter","volume":"2","author":"Manchanda","year":"2010","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Vasileiou, E., Pana, Z.D., and Tragiannidis, A. (2021). Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens, 10.","DOI":"10.3390\/pathogens10030373"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1099\/jmm.0.029439-0","article-title":"Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections","volume":"60","author":"Song","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/138161213804070285","article-title":"The rise of carbapenem-resistant Acinetobacter baumannii","volume":"19","author":"Evans","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/civ048","article-title":"Colistin-resistant Acinetobacter baumannii: Beyond carbapenem resistance","volume":"60","author":"Qureshi","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2016.07.007","article-title":"Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients","volume":"48","author":"Tsioutis","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a newly approved fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciz242","article-title":"Omadacycline: A novel tetracycline derivative with oral and intravenous formulations","volume":"69","author":"Watkins","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: Development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41429-019-0188-6","article-title":"In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates","volume":"72","author":"Ozger","year":"2019","journal-title":"J. Antibiot."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","article-title":"Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"30","author":"Li","year":"2022","journal-title":"J. Glob. Antimicrob. Res."},{"key":"ref_27","unstructured":"Clinical and Laboratory Standards Institute (2022). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [32nd ed.]. CLSI Document M100 ED32:2022."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhao, C., Wang, X., Zhang, Y., Wang, R., Wang, Q., Li, H., and Wang, H. (2019). In vitro activities of eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4093-1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.17159\/0379-4350\/2016\/v69a9","article-title":"Organocatalyzed mannich reactions on minocycline: Towards novel tetracycline antibiotics","volume":"69","author":"Chiwunze","year":"2016","journal-title":"S. Afr. J. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/mdr.2019.0423","article-title":"Activity of omadacycline and other tetracyclines against contemporary Gram-negative pathogens from New York City hospitals","volume":"27","author":"Iregui","year":"2021","journal-title":"Microb. Drug. Resist."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e02327-17","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mirzaei, B., Bazgir, Z.N., Goli, H.R., Iranpour, F., Mohammadi, F., and Babaei, R. (2020). Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-020-05224-w"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100077","DOI":"10.1016\/j.infpip.2020.100077","article-title":"Control and management of multidrug resistant Acinetobacter baumannii: A review of the evidence and proposal of novel approaches","volume":"2","author":"Weinberg","year":"2020","journal-title":"Infect. Prev. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jac\/dkm018","article-title":"High tigecycline resistance in multidrug-resistant Acinetobacter baumannii","volume":"59","author":"Leavitt","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1080\/22221751.2021.1948804","article-title":"Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf","volume":"10","author":"Hua","year":"2021","journal-title":"Emer. Microbes Infect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/phar.1493","article-title":"Adverse reactions associated with systemic polymyxin therapy","volume":"35","author":"Justo","year":"2015","journal-title":"Pharmacother"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","article-title":"Tigecycline: First of a new class of antimicrobial agents","volume":"26","author":"Rose","year":"2006","journal-title":"Pharmacother"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacother"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0960-894X(99)00216-4","article-title":"Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936","volume":"9","author":"Sum","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.14260\/jemds\/2021\/297","article-title":"and Bhat, P. Evaluation of tigecycline and minocycline susceptibility among clinical isolates of carbapenem-resistant Acinetobacter species","volume":"10","author":"Parveen","year":"2021","journal-title":"J. Evolution Med. Dent. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e0101021","DOI":"10.1128\/Spectrum.01010-21","article-title":"Tigecycline heteroresistance and resistance mechanism in clinical isolates of Acinetobacter baumannii","volume":"9","author":"Jo","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2000014","DOI":"10.1002\/bies.202000014","article-title":"Emerging high-level tigecycline resistance: Novel tetracycline destructases spread via the mobile Tet(X)","volume":"42","author":"Fang","year":"2020","journal-title":"BioEssays"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: The Tetracyclines Strike Back","volume":"53","author":"Heaney","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open For. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"104185","DOI":"10.1016\/j.meegid.2020.104185","article-title":"Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC","volume":"80","author":"Shi","year":"2020","journal-title":"Infect. Gen. Evol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1128\/AAC.18.5.798","article-title":"Interaction between aminoglycoside uptake and ribosomal resistance mutations","volume":"18","author":"Ahmad","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/AAC.00704-06","article-title":"Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides","volume":"51","author":"Jeannot","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/dnares\/dsu032","article-title":"Genomic analysis reveals distinct concentration-dependent evolutionary trajectories for antibiotic resistance in Escherichia coli","volume":"21","author":"Mogre","year":"2014","journal-title":"DNA Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1128\/AAC.03683-14","article-title":"Sigma S-dependent antioxidant defense protects stationary-phase Escherichia coli against the bactericidal antibiotic gentamicin","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","first-page":"7","article-title":"What do proton motive force driven multidrug resistance transporters have in common?","volume":"7","author":"Mazurkiewicz","year":"2005","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","article-title":"Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic","volume":"24","author":"Tanaka","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00542-22","DOI":"10.1128\/spectrum.00542-22","article-title":"Activity of omadacycline alone and in combination against carbapenem-nonsusceptible Acinetobacter baumannii with varying minocycline susceptibility","volume":"10","author":"Abbey","year":"2022","journal-title":"Microbiol. Spec."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jgar.2022.03.006","article-title":"Effect of omadacycline alone and in combination with meropenem against carbapenem-resistant Acinetobacter baumannii isolates","volume":"29","author":"Putra","year":"2022","journal-title":"J. Glob. Antimicrob. Res."},{"key":"ref_57","unstructured":"Hudzicki, J. (2012). Kirby-Bauer Disc Diffusion Susceptibility Test Protocol, American Society For Microbiology."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","article-title":"Determination of minimum inhibitory concentrations","volume":"48","author":"Andrews","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.41.5.1073","article-title":"Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies","volume":"41","author":"Bajaksouzian","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1128\/JCM.43.1.140-143.2005","article-title":"Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis","volume":"43","author":"Orhan","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_61","first-page":"232","article-title":"Rifampin resistance in carbapenem-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand","volume":"11","author":"Thapa","year":"2009","journal-title":"Nepal Med. Coll. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1128\/JCM.01588-06","article-title":"Multicenter studies of tigecycline disc diffusion susceptibility results for Acinetobacter spp.","volume":"45","author":"Jones","year":"2007","journal-title":"J. Clin. Microbiol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/10\/1298\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:58Z","timestamp":1760143078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/10\/1298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":62,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["antibiotics11101298"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11101298","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}